Vaccine-Induced Immune Thrombotic Thrombocytopenia Two Years Later: Should It Still Be on the Scientific Agenda?

Abstract

Vaccine-induced immune thrombotic thrombocytopenia (VITT) was recognized around 2 years ago, at the beginning of the anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination campaign, as a rare but life-threatening complication of adenoviral vector vaccines. Two years later, the coronavirus disease 2019 (COVID-19) pandemic has been tamed, although not defeated, and the vaccines provoking VITT have been abandoned in most high-income countries, thus why should we still speak about VITT? Because a significant fraction of the world population has not been vaccinated yet, especially in low/middle-income countries that can only afford adenoviral vector-based vaccines, because the adenoviral vector platform is being used for the development of a large series of new vaccines for other transmissible diseases, and lastly because there are some clues suggesting that VITT may not be exclusive to anti-SARS-CoV-2 vaccines. Therefore, a deep understanding of this new syndrome is highly warranted as well as the awareness that we still miss some crucial insight into its pathophysiology and on some aspects of its management. This snapshot review aims to portray our knowledge on VITT, focusing on its clinical presentation, pathophysiological insight, diagnostic and management strategies, and to pinpoint the main unmet needs, highlighting the aspects on which research should focus in the near future.

Keywords

adenoviral vector-based vaccines - antiplatelet - COVID-19 - SARS-CoV-2 - thrombotic thrombocytopenia

Publication History

Received: 28 April 2023

Accepted: 05 June 2023

Accepted Manuscript online:
07 June 2023

Article published online:
07 August 2023

• References

• 1 COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet 2022; 399 (10334): 1513-1536
• 2 Ssentongo P, Ssentongo AE, Voleti N. et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2022; 22 (01) 439
• 3 Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022; 22 (09) 1293-1302
• 4 Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021; 372: n699
• 5 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
• 6 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2130
• 7 Scully M, Singh D, Lown R. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (23) 2202-2211
• 8 Holder J. . Tracking coronavirus vaccinations around the world. The New York Times [Internet]. 2023. Accessed April 06, 2023 at: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html
• 9 Kanack AJ, Laegreid IJ, Johansen S, Reikvam H, Ahlen MT, Padmanabhan A. Human papilloma virus vaccine and VITT antibody induction. Am J Hematol 2022; 97 (10) E363-E364
• 10 Greinacher A, Langer F, Schonborn L. et al. Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica 2022; 107 (05) 1219-1221
• 11 Commissioner O of the. . COVID-19 frequently asked questions. FDA [Internet]. 2023. Accessed March 27, 2023 at: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-questions
• 12 EMA. . COVID-19 vaccines [Internet]. European Medicines Agency. 2021. Accessed April 14, 2023 at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines
• 13 See I, Su JR, Lale A. et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021; 325 (24) 2448-2456
• 14 Pottegård A, Lund LC, Karlstad Ø. et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ 2021; 373: n1114
• 15 Ashrani AA, Crusan DJ, Petterson T, Bailey K, Heit JA. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination. JAMA Intern Med 2022; 182 (01) 80-83
• 16 Dag Berild J, Bergstad Larsen V, Myrup Thiesson E. et al. Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries. JAMA Netw Open 2022; 5 (06) e2217375
• 17 See I, Lale A, Marquez P. et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021. Ann Intern Med 2022; 175 (04) 513-522
• 18 Herrera-Comoglio R, Lane S. Vaccine-induced immune thrombocytopenia and thrombosis after the Sputnik V vaccine. N Engl J Med 2022; 387 (15) 1431-1432
• 19 Cines DB, Greinacher A. Vaccine-induced immune thrombotic thrombocytopenia. Blood 2023; 141 (14) 1659-1665
• 20 Paez Alacron ME, Greinacher A. “Vaccine-induced immune thrombotic thrombocytopenia (VITT)-Update on diagnosis and management considering different resources”: Comment. J Thromb Haemost 2022; 20 (11) 2707-2708
• 21 Krzywicka K, van de Munckhof A, Zimmermann J. et al. Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. Blood 2022; 139 (17) 2720-2724
• 22 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385 (18) 1680-1689
• 23 Kim AY, Woo W, Yon DK. et al. Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a systematic review and meta-analysis. Int J Infect Dis 2022; 119: 130-139
• 24 Bourguignon A, Arnold DM, Warkentin TE. et al. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 385 (08) 720-728
• 25 Elberry MH, Abdelgawad HAH, Hamdallah A. et al. A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines. J Thromb Thrombolysis 2022; 53 (04) 798-823
• 26 Tran H, Deng L, Wood N. et al. The clinicalpathological features of vaccine-induced immune thrombocytopenia and thrombosis (VITT) following ChAdOx1 (AstraZeneca AZD1222) vaccination and case outcomes in Australia. Blood 2022; 140: 5654-5655
• 27 Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017; 15 (11) 2099-2114
• 28 Warkentin TE, Greinacher A. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thromb Res 2021; 204: 40-51
• 29 Greinacher A, Selleng K, Palankar R. et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 2021; 138 (22) 2256-2268
• 30 Baker AT, Boyd RJ, Sarkar D. et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv 2021; 7 (49) eabl8213
• 31 Michalik S, Siegerist F, Palankar R. et al. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Haematologica 2022; 107 (04) 947-957
• 32 Weber C, von Hundelshausen P, Siess W. VITT after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 385 (23) 2203-2204
• 33 Jin J, Qiao S, Liu J. et al. Neutrophil extracellular traps promote thrombogenicity in cerebral venous sinus thrombosis. Cell Biosci 2022; 12 (01) 114
• 34 Laridan E, Denorme F, Desender L. et al. Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol 2017; 82 (02) 223-232
• 35 Denorme F, Portier I, Rustad JL. et al. Neutrophil extracellular traps regulate ischemic stroke brain injury. J Clin Invest 2022; 132 (10) e154225
• 36 Johnston I, Sarkar A, Hayes V. et al. Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. Blood 2020; 135 (15) 1270-1280
• 37 Hayes V, Johnston I, Arepally GM. et al. Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. J Clin Invest 2017; 127 (03) 1090-1098
• 38 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
• 39 Leung HHL, Perdomo J, Ahmadi Z. et al. NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia. Nat Commun 2022; 13 (01) 5206
• 40 Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 2021; 596 (7873): 565-569
• 41 Huynh A, Arnold DM, Michael JV. et al. Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. Blood Adv 2023; 7 (02) 246-250
• 42 Kanack AJ, Bayas A, George G. et al. Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood 2022; 140 (01) 73-77
• 43 Wang JJ, Armour B, Chataway T. et al. Vaccine-induced immune thrombotic thrombocytopenia is mediated by a stereotyped clonotypic antibody. Blood 2022; 140 (15) 1738-1742
• 44 Nicolai L, Leunig A, Pekayvaz K. et al. Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration. Blood 2022; 140 (05) 478-490
• 45 Petito E, Colonna E, Falcinelli E. et al. Anti-severe acute respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers. Br J Haematol 2022; 198 (02) 257-266
• 46 Lombardi L, Maiorca F, Marrapodi R. et al. Distinct platelet crosstalk with adaptive and innate immune cells after adenoviral and mRNA vaccination against SARS-CoV-2. J Thromb Haemost 2023; 21 (06) 1636-1649
• 47 Ostrowski SR, Søgaard OS, Tolstrup M. et al. Inflammation and platelet activation after COVID-19 vaccines - possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis. Front Immunol 2021; 12: 779453
• 48 Campello E, Bulato C, Simion C. et al. Assessing clinically meaningful hypercoagulability after COVID-19 vaccination: a longitudinal study. Thromb Haemost 2022; 122 (08) 1352-1360
• 49 de Laat B, Stragier H, de Laat-Kremers R. et al. Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S. Front Cardiovasc Med 2022; 9: 966028
• 50 Gresele P, Momi S, Marcucci R, Ramundo F, De Stefano V, Tripodi A. Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. Haematologica 2021; 106 (12) 3034-3045
• 51 Kowarz E, Krutzke L, Külp M. et al. Vaccine-induced COVID-19 mimicry syndrome. eLife 2022; 11: e74974
• 52 Almuqrin A, Davidson AD, Williamson MK. et al. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. Genome Med 2021; 13 (01) 43
• 53 McCracken IR, Saginc G, He L. et al. Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation 2021; 143 (08) 865-868
• 54 De Michele M, Piscopo P, Crestini A. et al. Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein. Haematologica 2022; 107 (07) 1687-1692
• 55 Campbell RA, Boilard E, Rondina MT. Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets?. J Thromb Haemost 2021; 19 (01) 46-50
• 56 Ogata AF, Cheng C-A, Desjardins M. et al. Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis 2022; 74 (04) 715-718
• 57 Stebbings R, Jones C, Cotton P. et al. SARS-CoV-2 spike protein expression in vitro and hematologic effects in mice vaccinated with AZD1222 (ChAdOx1 nCoV-19). Front Immunol 2022; 13: 836492
• 58 Schönborn L, Seck SE, Thiele T, Warkentin TE, Greinacher A. SARS-CoV-2 infection in patients with a history of VITT. N Engl J Med 2022; 387 (01) 88-90
• 59 Craddock V, Mahajan A, Spikes L. et al. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol 2023; 95 (02) e28568
• 60 Nazy I, Sachs UJ, Arnold DM. et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost 2021; 19 (06) 1585-1588
• 61 Oldenburg J, Klamroth R, Langer F. et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 2021; 41 (03) 184-189
• 62 Gresele P, Marietta M, Ageno W. et al. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). Blood Transfus 2021; 19 (04) 281-283
• 63 Zazzeron L, Rosovsky RP, Bittner EA, Chang MG. Comparison of published guidelines for the diagnosis and the management of vaccine-induced immune thrombotic thrombocytopenia. Crit Care Explor 2021; 3 (09) e0519
• 64 Thrombosis with Thrombocytopenia Syndrome - Hematology.org [Internet]. Accessed April 18, 2023 at: https://www.hematology.org:443/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
• 65 Favaloro EJ, Pasalic L, Lippi G. Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). Clin Chem Lab Med 2021; 60 (01) 7-17
• 66 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2022; (online ahead of print). DOI: 10.1055/s-0042-1758818.
• 67 Azorin DG. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). World Health Organization; 2023. Accessed July, 2023 at: https://www.who.int/publications/i/item/9789240061989
• 68 Favaloro EJ, Clifford J, Leitinger E. et al. Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: a multicenter study comprising 1284 patients. J Thromb Haemost 2022; 20 (12) 2896-2908
• 69 Vayne C, Rollin J, Gruel Y. et al. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med 2021; 385 (04) 376-378
• 70 Platton S, Bartlett A, MacCallum P. et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost 2021; 19 (08) 2007-2013
• 71 Terpos E, Politou M, Ntanasis-Stathopoulos I. et al. High prevalence of anti-PF4 antibodies following ChAdOx1 nCov-19 (AZD1222) vaccination even in the absence of thrombotic events. Vaccines (Basel) 2021; 9 (07) 712
• 72 Liu Q, Miao H, Li S. et al. Anti-PF4 antibodies associated with disease severity in COVID-19. Proc Natl Acad Sci U S A 2022; 119 (47) e2213361119
• 73 Schönborn L, Thiele T, Esefeld M. et al. Quantitative interpretation of PF4/heparin-EIA optical densities in predicting platelet-activating VITT antibodies. J Thromb Haemost 2022; 20 (11) 2579-2586
• 74 Craven B, Lester W, Boyce S. et al. Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis. Blood 2022; 139 (16) 2553-2560
• 75 Schönborn L, Thiele T, Kaderali L, Greinacher A. Decline in pathogenic antibodies over time in VITT. N Engl J Med 2021; 385 (19) 1815-1816
• 76 Schönborn L, Thiele T, Kaderali L. et al. Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient. Blood 2022; 139 (12) 1903-1907
• 77 Kanack AJ, Singh B, George G. et al. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol 2022; 97 (05) 519-526
• 78 van de Munckhof A, Lindgren E, Kleinig TJ. et al; Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group. Outcomes of cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after the acute phase. Stroke 2022; 53 (10) 3206-3210
• 79 Panagiota V, Dobbelstein C, Werwitzke S. et al. Long-term outcomes after vaccine-induced thrombotic thrombocytopenia. Viruses 2022; 14 (08) 1702
• 80 Arnold DM. Heparin or nonheparin anticoagulants for VITT. Blood 2022; 139 (23) 3358-3359
• 81 Gabarin N, Arnold DM, Nazy I, Warkentin TE. Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol 2022; 59 (02) 89-96
• 82 Roberge G, Carrier M. Long VITT: a case report. Thromb Res 2023; 223: 78-79
• 83 Lacy J, Pavord S, Brown KE. VITT and second doses of Covid-19 vaccine. N Engl J Med 2022; 386 (01) 95
• 84 Elalamy I, Gerotziafas G, Alamowitch S. et al; Scientific Reviewer Committee. SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia. Thromb Haemost 2021; 121 (08) 982-991
• 85 Mouta Nunes de Oliveira P, Mendes-de-Almeida DP, Bertollo Gomes Porto V. et al; Brazillian VITT Investigative Collaboration Group. Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: description of a series of 39 cases in Brazil. Vaccine 2022; 40 (33) 4788-4795
• 86 Salih F, Schönborn L, Kohler S. et al. Vaccine-induced thrombocytopenia with severe headache. N Engl J Med 2021; 385 (22) 2103-2105
• 87 Salih F, Kohler S, Schönborn L. et al. Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway. Eur Heart J Open 2022; 2: oeac036
• 88 Schultz NH, Søraas AVL, Sørvoll IH. et al. Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: a cohort study. J Stroke Cerebrovasc Dis 2023; 32 (01) 106860
• 89 Perry RJ, Tamborska A, Singh B. et al; CVT After Immunisation Against COVID-19 (CAIAC) collaborators. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet 2021; 398 (10306): 1147-1156
• 90 Scutelnic A, Krzywicka K, Mbroh J. et al. Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination. Ann Neurol 2022; 92 (04) 562-573
• 91 Hwang J, Park SH, Lee SW. et al. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. Eur Heart J 2021; 42 (39) 4053-4063
• 92 Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol 2022; 9 (01) e73-e80
• 93 Singh A, Toma F, Uzun G. et al. The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood 2022; 139 (23) 3430-3438
• 94 Sallard E, Zhang W, Aydin M, Schröer K, Ehrhardt A. The adenovirus vector platform: novel insights into rational vector design and lessons learned from the COVID-19 vaccine. Viruses 2023; 15 (01) 204
• 95 Nouailles G, Adler JM, Pennitz P. et al. Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nat Microbiol 2023; 8 (05) 860-874
• 96 Sallard E, Pembaur D, Schröer K. et al. Adenovirus type 34 and HVR1-deleted adenovirus type 5 do not bind to PF4: clearing the path towards vectors without thrombosis risk. Microbiology. 2022. Accessed July 20, 2023 at: http://biorxiv.org/lookup/doi/10.1101/2022.11.07.515483
• 97 Ortel TL, Kitchens CS, Erkan D. et al. Clinical causes and treatment of the thrombotic storm. Expert Rev Hematol 2012; 5 (06) 653-659
• 98 Todd S, Hemmaway C, Nagy Z. Catastrophic thrombosis in idiopathic hypereosinophilic syndrome. Br J Haematol 2014; 165 (04) 425
• 99 Ortel TL, Erkan D, Kitchens CS. How I treat catastrophic thrombotic syndromes. Blood 2015; 126 (11) 1285-1293
• 100 Kropf J, Cheyney S, Vachon J, Flaherty P, Vo M, Carlan SJ. Extensive catastrophic thromboses from elevation of factor VIII. Clin Pract 2020; 10 (03) 1265
• 101 Rodriguez JA, D'Silva K, Kohler M, Ghoshhajra B, Hedgire S. Catastrophic thrombotic storm. Clin Imaging 2021; 74: 64-66
• 102 Smith CW, Montague SJ, Kardeby C. et al. Antiplatelet drugs block platelet activation by VITT patient serum. Blood 2021; 138 (25) 2733-2740